Wed, July 27, 2011
[ Wed, Jul 27th 2011 ]: Market Wire
Electromed, Inc. Presents Distinguished Service Award to Jerry Cahill
[ Wed, Jul 27th 2011 ]: Market Wire
Aetna Joins Effort to Increase Disability Awareness, Planning and Prevention
[ Wed, Jul 27th 2011 ]: Market Wire
U.S. Physical Therapy Makes 20 Clinic Acquisition
[ Wed, Jul 27th 2011 ]: Market Wire
CytRx Prices $20.4 Million Public Offering
[ Wed, Jul 27th 2011 ]: Market Wire
Affymax and Takeda Announce FDA Acceptance of New Drug Application for Peginesatide
[ Wed, Jul 27th 2011 ]: Market Wire
POZEN Welcomes Dr. Seth A. Rudnick to the Board of Directors
[ Wed, Jul 27th 2011 ]: Market Wire
Repligen Reports First Quarter Fiscal Year 2012 Financial Results
[ Wed, Jul 27th 2011 ]: Market Wire
Positive Data Demonstrating dermaPACE Safely Heal .. Highlighted in CME Presentation at the American P
[ Wed, Jul 27th 2011 ]: Market Wire
Columbia Laboratories Licenses STRIANT Canadian T .. Marketing Rights to Invaron Pharmaceuticals Inc.
[ Wed, Jul 27th 2011 ]: Market Wire
Illumina to Present at Leerink Swann Life Science Tools and Diagnostics Roundtable
Tue, July 26, 2011
[ Tue, Jul 26th 2011 ]: Market Wire
Biogen Idec en Swedish Orphan Biovitrum presenter .. et langdurig werkzame recombinante factor VIII ti
[ Tue, Jul 26th 2011 ]: Market Wire
Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas
[ Tue, Jul 26th 2011 ]: Market Wire
Interim Data from Phase 2 Study of Combination Re .. CIVEKa" Suggest Potential to Treat Genotype 1 Hep
[ Tue, Jul 26th 2011 ]: Market Wire
Ligand Partner GlaxoSmithKline Receives Positive .. LE1 Study in Hepatitis C-Related Thrombocytopenia
[ Tue, Jul 26th 2011 ]: Market Wire
Biogen Idec Reports Second Quarter 2011 Results
[ Tue, Jul 26th 2011 ]: Market Wire
Biogen Idec y Swedish Orphan Biovitrum presentan .. factor VIII recombinante con accin duradera en la
[ Tue, Jul 26th 2011 ]: Market Wire
American Anesthesiology Announces the Acquisition of Group Practice Based in Palm Beach County, FL
[ Tue, Jul 26th 2011 ]: Market Wire
Dyax Corp. and Kadmon Corporation Announce Antibody Library License Agreement
[ Tue, Jul 26th 2011 ]: Market Wire
Arrowhead Research Announces Oncology Expert Timo .. Triche to Join Calando Scientific Advisory Board
[ Tue, Jul 26th 2011 ]: Market Wire
Biogen Idec et Swedish Orphan Biovitrum pr©sente .. ement avec le facteur VIII recombinant action pro
[ Tue, Jul 26th 2011 ]: Market Wire
Biogen Idec und Swedish Orphan Biovitrum legen Da .. wirkenden rekombinanten Faktor VIII auf der Tagun
Mon, July 25, 2011
[ Mon, Jul 25th 2011 ]: Market Wire
Threshold Pharmaceuticals Announces Initiation of .. -302 in Combination with Bevacizumab at Universit
[ Mon, Jul 25th 2011 ]: Market Wire
Response Genetics Announces Search for New CEO
[ Mon, Jul 25th 2011 ]: Market Wire
Celldex Therapeutics to Report Second Quarter 201 .. ts and Host Corporate 2011 Objectives Update Call
[ Mon, Jul 25th 2011 ]: Market Wire
Alnylam and MIT Collaborators Discover Novel aCor .. ticles for Systemic Delivery of RNAi Therapeutics
[ Mon, Jul 25th 2011 ]: Market Wire
Amyris Commissions Commercial Production Operations at Antibiticos
[ Mon, Jul 25th 2011 ]: Market Wire
Amyris and Firmenich Announce Expansion of Collaboration
[ Mon, Jul 25th 2011 ]: Market Wire
Amyris pronta para produo comercial na Antibiticos
[ Mon, Jul 25th 2011 ]: Market Wire
Amyris e Firmenich anunciam expanso de colaborao
[ Mon, Jul 25th 2011 ]: Market Wire
Illumina Announces First Customer Shipments of the Omni5 BeadChip
[ Mon, Jul 25th 2011 ]: Market Wire
Acorda Therapeutics to Host Conference Call to Di .. Quarter 2011 Financial Results on August 1, 2011
Sat, July 23, 2011
[ Sat, Jul 23rd 2011 ]: Market Wire
Mettler-Toledo International Inc. to Webcast Investor Presentation
Fri, July 22, 2011
[ Fri, Jul 22nd 2011 ]: Market Wire
Watson Confirms JALYNa" Patent Challenge
[ Fri, Jul 22nd 2011 ]: Market Wire
Electromed, Inc. Names Diane M. Erdman as HR Director
[ Fri, Jul 22nd 2011 ]: Market Wire
30 p.m. ET to Discuss Financial Results for the Second Quarter and Six Months Ended June 30, 2011
[ Fri, Jul 22nd 2011 ]: Market Wire
Dr. Reddya?s Acquires Prescription Business of JB .. s & Pharmaceuticals in Russia & Other CIS Markets
[ Fri, Jul 22nd 2011 ]: Market Wire
International Drug & Explosives Detection Company .. From India for Drug Detectors and Explosive Ident
[ Fri, Jul 22nd 2011 ]: Market Wire
Centric Health to Acquire Majority Interest in Performance Medical Group
Thu, July 21, 2011
[ Thu, Jul 21st 2011 ]: Market Wire
Aetna Hosts White House Health Technology Innovation Summit
[ Thu, Jul 21st 2011 ]: Market Wire
Bull & Lifshitz, LLP Announces Investigation of Icagen, Inc.
[ Thu, Jul 21st 2011 ]: Market Wire
Law Offices of Howard G. Smith Announces Investigation of Allos Therapeutics, Inc.
[ Thu, Jul 21st 2011 ]: Market Wire
Faruqi & Faruqi, LLP Announces Investigation of Jiangbo Pharmaceuticals, Inc.
[ Thu, Jul 21st 2011 ]: Market Wire
Bull & Lifshitz, LLP Announces Investigation of Allos Therapeutics, Inc.
[ Thu, Jul 21st 2011 ]: Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Acti .. uit against Mindray Medical International Limited
[ Thu, Jul 21st 2011 ]: Market Wire
Fitch Upgrades Boston Scientific's IDR to 'BBB-'; Outlook to Stable
[ Thu, Jul 21st 2011 ]: Market Wire
Thermo Fisher Scientific Signs Agreement to Make .. iomarker Assays Available on Alere Triage Systems
[ Thu, Jul 21st 2011 ]: Market Wire
Five Star Quality Care, Inc. Second Quarter Conference Call Scheduled for Thursday, July 28th
[ Thu, Jul 21st 2011 ]: Market Wire
El antirretroviral en fase de investigacin de Gil .. da, no es inferior a raltegravir dos veces al da

Biogen Idec e Swedish Orphan Biovitrum presentano dati sulla terapia di lunga durata con fattore VIII ricombinante alla riunion

KYOTO, Giappone--([ BUSINESS WIRE ])--[ Biogen Idec ](NASDAQ: BIIB) e[ Swedish Orphan Biovitrum ](STO: SOBI) hanno annunciato in data odierna i dati di uno studio di fase 1/2a indicanti che la proteina di fusione Fc costituita da fattore VIII totalmente ricombinante di lunga durata dell'azienda (rFVIIIFc) era ben tollerata e ha dimostrato un aumento di circa 1,7 volte dell'emivita rispetto ad Advate® (fattore ricombinante anti-emofilico, metodo senza plasma/albumina, rFVIII), prodotto disponibile commercialmente a base di fattore VIII, in 16 pazienti trattati previamente affetti da emofilia A grave.

Galleria Fotografica/Multimediale Disponibile: [ http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6805603&lang=it ]